Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
I am looking for
added new label for I am looking for
Advanced Filters
Found 323 clinical trials
Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal Gastroesophageal and Renal Cancers

therapy in patients with metastatic colorectal cancer, metastatic gastroesophageal cancer and metastatic renal cell carcinoma.

metastatic renal cell carcinoma
metastatic cancer
curative surgery
measurable disease
modified folfox6 regimen
  • 02 Jun, 2021
  • 47 locations
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer The PDIGREE Study

cabozantinib in patients with untreated renal cell carcinoma that has spread to other parts of the body. The addition of cabozantinib to the usual treatment may make it work better. Immunotherapy with

step 2
programmed cell death 1 ligand 1
neutrophil count
metastatic renal cell carcinoma
  • 13 Jun, 2021
  • 673 locations
Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy

This phase III trial compares nephrectomy (surgery to remove a kidney or part of a kidney) with nivolumab to the usual approach of nephrectomy followed by standard post-operative follow-up and monitoring, in treating patients with kidney cancer that is limited to a certain part of the body (localized). Nivolumab is …

primary tumor
major surgery
programmed cell death 1 ligand 1
radiofrequency ablation
renal function
  • 13 Jun, 2021
  • 281 locations
A Study of PDR001 in Combination With LCL161 Everolimus or Panobinostat

The purpose of this study is to combine the PDR001 checkpoint inhibitor with several agents with immunomodulatory activity to identify the doses and schedule for combination therapy and to preliminarily assess the safety, tolerability, pharmacological and clinical activity of these combinations.

  • 13 May, 2021
  • 33 locations
PROMOTE: Identifying Predictive Markers of Response for Genitourinary Cancer

This is a tissue and blood collection protocol requiring image-guided biopsies of metastatic prostate cancer and other genitourinary malignancies including renal cell carcinoma and urothelial

prostate cancer metastatic
luteinizing hormone
bone scan
  • 04 Jun, 2021
  • 1 location
Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers

CK-301 (cosibelimab) is a fully human monoclonal antibody of IgG1 subtype that directly binds to Programmed Death-Ligand 1 (PD-L1) and blocks its interactions with the Programmed Death-1 (PD-1) and B7.1 receptors. The primary objectives of this study are to assess the safety, tolerability and efficacy of CK-301 when administered intravenously …

endometrial carcinoma
programmed cell death 1 ligand 1
metastatic cancer
stage iv nsclc
  • 22 Mar, 2021
  • 47 locations
A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors

The purpose of this study is to evaluate MEDI5752 in adult subjects with advanced solid tumors, when administered as a single agent or combined with chemotherapy.

progressive disease
programmed cell death 1 ligand 1
hormone therapy
  • 03 Jun, 2021
  • 36 locations
Minocycline Attenuate Postoperative Cognitive Dysfunction and Delirium

Postoperative cognitive dysfunction (POCD) and postoperative delirium occurs mainly in aged patients. POCD and POD may increase the mortality and morbidity. However, the mechanism of POCD is not clear yet and no effective therapy method was proved. According to previous study, the neuroinflammation is the main reason both for POCD …

  • 23 Jan, 2021
  • 5 locations
Study of MK-4830 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4830-001)

carcinoma (NSCLC), and MK-4830 in combination with pembrolizumab + lenvatinib in renal cell cancer; and to evaluate objective response rate (ORR) in participants with advanced solid tumors treated with MK

solid tumor
measurable disease
antineoplastic agents
metastatic malignant solid tumor
  • 23 May, 2021
  • 26 locations
A Phase II Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma

This is a Phase II, multicenter, open-label, single arm, 2-stage study of tazemetostat 800 mg BID (twice daily) and 1600 mg QD (once daily). Subjects will be screened for eligibility within 21 days of the planned date of the first dose of tazemetostat and enrolled into one of 8 cohorts: …

beta human chorionic gonadotropin
measurable disease
solid tumour
kidney function tests
growth factor
  • 31 May, 2021
  • 25 locations